COMP <GO>
TECH vs NBIX // GROSS PROFIT MARGIN
Bio-Techne Corp (NASDAQ) VS. Neurocrine Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: TECH 2
— NBIX 12
▲ GROSS PROFIT MARGIN LEADER: NBIX
LAST: $72.71 (+0.03%) • MKT CAP: $11.40B
gross-margins
64.80%
LAST: $146.38 (+0.58%) • MKT CAP: $14.88B
gross-margins
96.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TECH VS. NBIX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TECH | NBIX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 64.80% | 96.00% | -31.20 | NBIX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.40% | 15.70% | -12.30 | NBIX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 91.3x | 22.8x | +68.50 | NBIX | /valuation <GO> |
| Free Cash Flow Yield | 2.25% | 5.03% | -2.78 | NBIX | /fcf-yield <GO> |
| Operating Margin | 8.40% | 21.60% | -13.20 | NBIX | /operating-margins <GO> |
| Net Profit Margin | 6.00% | 16.70% | -10.70 | NBIX | /net-margins <GO> |
| Revenue Growth (YoY) | 5.20% | 21.40% | -16.20 | NBIX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.44% | 0.00% | +0.44 | TECH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.12 | 8.13 | -1.01 | NBIX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | NBIX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.3 | 56.1 | +3.20 | TECH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 1.13 | -0.25 | NBIX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 26.1x | +113.90 | NBIX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.40B | $14.88B | -$3.48B | NBIX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TECH REV | NBIX REV | TECH GROSS % | NBIX GROSS % | TECH FCF | NBIX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.22B | $2.86B | 64.8% | 98.2% | $256.6M | $748.7M |
| FY 2024 | $1.16B | $2.36B | 66.4% | 98.6% | $236.1M | $557.2M |
| FY 2023 | $1.14B | $1.89B | — | — | $203.2M | $305.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TECH // BETA 0.88
NBIX // BETA 1.13